American Herbal Products Association (AHPA) > News

Lessons in herb safety from The Cleveland Clinic Chinese Herbal Medicine Program

Clinic reports only six mild adverse events since 2014

Nationally board-certified acupuncturist and Chinese herbalist at the Cleveland Clinic Galina Roofener shared safety data and lessons learned from the Cleveland Clinic Wellness Institute’s Traditional Chinese Herbal Medicine (TCHM) Program at her keynote delivered at the American Herbal Products Association’s (AHPA’s) 7th Annual Botanical Congress presented on Nov. 10 in Las Vegas at the SupplySide West trade show.

FDA Update by ODSP Director Steven Tave Presented at 7th Annual AHPA Botanical Congress

Tave outlines collaborations between FDA and supplement industry to ensure consumer safety

The American Herbal Products Association’s (AHPA’s) 7th Annual Botanical Congress featured a Food and Drug Administration (FDA) update by Steven Tave, FDA’s Director of the Office of Dietary Supplement Programs (ODSP), who highlighted recent collaborations between the responsible supplement industry and FDA toward the shared goal of a well-regulated dietary supplement market.

A look at the 115th and 116th Congresses and the case against mandatory listing of dietary supplement labels in the November 2018 AHPA Report!

November 2018 AHPA Report

AHPA Chief Science Officer presents at Hemp Industries Association 25th Annual Conference

Dr. Johnson discusses quality standards for farmers, formulators, and finished product manufacturers

AHPA Chief Science Officer Dr. Holly Johnson discussed quality standards for hemp farmers, formulators, and finished product manufacturers at the Hemp Industries Association (HIA) 25th Annual Conference held Nov. 2-5 in Los Angeles.

Dietary Supplement Trade Associations Warn Consumers of Dangerous Substance Illegally Posing as a Dietary Supplement

Supplement industry sounds the alarm about the dangers of “phenibut,” a substance being illegally marketed in products fraudulently labeled as dietary supplements

Developed and used as a drug in the former Soviet Union for its supposed brain-enhancing properties, phenibut is not approved as a drug in the United States, nor does it meet the regulatory requirements to be sold in, or as, a dietary supplement. The ingredient should be considered dangerous, and has been associated with potentially serious side effects and great risk for addiction.

AHPA provides cGMP resources to herbalists attending AHG Symposium

AHG awards Dr. Zimmermann for cGMP compliance poster

AHPA Chief Information Analyst Merle Zimmermann, Ph.D. provided cGMP compliance resources to herbalists attending the American Herbalist Guild (AHG) 29th Annual Symposium in Georgia last week.

AHPA corrects JAMA article that misidentifies illegal drugs as dietary supplements

Products adulterated with undeclared drugs are not dietary supplements

In a letter to the editor submitted to JAMA Open Network, American Herbal Products Association (AHPA) President Michael McGuffin stressed that the herbal products industry shares concerns about unapproved drugs masquerading as dietary supplements, as outlined in a recent article, but also highlighted that the authors mislead readers by failing to make a clear distinction between unlawful, misbranded drugs and legal dietary supplements.

Rupa Das to serve as Interim Chair of AHPA's Board of Trustees

AHPA thanks Graham Rigby for his leadership

The American Herbal Products Association (AHPA) has appointed Rupa Das as Chair of the AHPA Board of Trustees until March 2019.

AHPA launches sustainability subcommittee, formalizing ongoing efforts

Subcommittee to further AHPA’s ongoing efforts to ensure sustainable supplies of valuable botanicals

AHPA's Botanical Raw Materials Committee has launched a Sustainability Subcommittee to further AHPA’s ongoing efforts to ensure sustainable supplies of valuable botanicals. The subcommittee will be a vehicle for increasing awareness of sustainability issues and best practices, provide a forum to discuss and develop industry-wide standards, and promote existing sustainability initiatives throughout the industry.

Arizona Board of Pharmacy reportedly considers most dietary supplements to be nonprescription drugs

Board is pushing supplement companies that sell in the state to register as "wholesaler of nonprescription drugs"

The Arizona State Board of Pharmacy recently began interpreting its authority in a manner that implies that virtually every company that manufacturers or sells dietary supplements in the state will need to register as a nonprescription drug facility. If the board is successful and persistent in this approach, it could significantly disrupt dietary supplement business in the state.

Latest News

Subscribe >>